JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8706 BLU9931

Target: FGFR

Summary: FGFR4 inhibitor,potent and irreversible

≥50.9 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A8253 PD 173074

Target: VEGFR|FGFR

Summary: FGFR inhibitor

≥26.18 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A2597 Brivanib (BMS-540215)

Target: VEGFR|FGFR|Flk1

Summary: VEGFR-2 inhibitor,ATP-competitive

insoluble in H2O; ≥18.5 mg/mL
A2024 PD168393

Target: PDGFR|FGFR|EGFR|PKC|insulin

Summary: EGFR inhibitor
A8350 AZD4547

Target: FGFR

Summary: FGFR inhibitor

≥23.2 mg/mL
B4904 ACTB-1003

Target: VEGFR|FGFR|Tie-2|RSK|p70 S6K

Summary: FGFR1 inhibitor

insoluble in H2O; ≥18.15 mg/mL
B5953 Dovitinib (TKI258) Lactate

Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).

insoluble in EtOH; ≥10.62 mg/mL
A3014 BGJ398
1 Citation

Target: FGFR

Summary: FGFR inhibitor ,potent and selective

insoluble in H2O; insoluble in EtOH; ≥7 mg/mL